Neville Mistry, MD
Interventional Cardiology · Las Vegas, NVNPI 1881803187
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (46.1%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Abbott at 51.0% of the total. 2025 is the largest year on record at $15,951, 3.3 times the $4,860 reported in 2019.
Across 258 payments — averaging $140.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$19K
- Abiomed$7K
- Medtronic$4K
- Shockwave Medical, Inc$3K
- Edwards Lifesciences$1K
- Inari Medical, Inc.$351
- plus $2K from 17 others
Across 1 payment — averaging $3750.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$4K
What the payments were for
- Consulting fees$4,43012%
- Speaking & faculty fees$11,37531%
- Travel & lodging$3,63710%
- Food & beverage$16,77446%
- Gifts$1590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 103 | $18,545 |
| Abiomed | 42 | $7,473 |
| Medtronic(2 entities) | 44 | $3,877 |
| Shockwave Medical, Inc | 14 | $2,925 |
| Edwards Lifesciences | 7 | $1,249 |
| Inari Medical, Inc. | 3 | $351 |
| AstraZeneca | 2 | $224 |
| Philips North America LLC | 6 | $211 |
| W. L. Gore & Associates, Inc. | 1 | $173 |
| Chiesi USA, Inc. | 2 | $159 |
| Amgen | 3 | $157 |
| Pfizer | 2 | $144 |
| Novartis | 6 | $127 |
| Aurinia Pharma U.S., Inc. | 1 | $125 |
| Cardiva Medical, Inc. | 2 | $113 |
| Heartflow, Inc. | 2 | $109 |
| BD | 1 | $92 |
| Cardiovascular Systems Inc. | 6 | $82 |
| Johnson & Johnson | 5 | $74 |
| E.r. Squibb & Sons, L.L.C. | 3 | $69 |
| Cvrx, Inc. | 1 | $54 |
| Irhythm Technologies, Inc. | 1 | $22 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NAVITOR$9,318
- Impella$5,659
- AMPLATZER AMULET$3,296
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$2,550
- CoreValve Evolut$1,375
- PORTICO$965
- TRICLIP$949
- COREVALVE EVOLUT R$797
- CARDIOMEMS$711
- Edwards SAPIEN 3 Transcatheter Heart Valve$566
- MitraClip$532
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$505
- Endurant$396
- FLOWTRIEVER CATHETER, S$340
- CT THROMBECTOMY SYSTEM KIT$340
- XIENCE SIERRA$289
- Confirm Rx$239
- GORE CARDIOFORM Septal Occluder$173
- ENDURANT IIS$161
- Diamondback Coronary$152
How this compares
$36,374 in reported general payments places this provider in the 85th percentile of 62 interventional cardiology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 181 | $249,848 |
| EntrestoSacubitril/Valsartan | 100 | $125,662 |
| Repatha SureclickEvolocumab | 51 | $41,784 |
| XareltoRivaroxaban | 23 | $28,180 |
| BrilintaTicagrelor | 26 | $24,713 |
| JardianceEmpagliflozin | 20 | $22,783 |
| Repatha SyringeEvolocumab | 15 | $14,252 |
| Atorvastatin Calcium | 356 | $3,251 |
| Ranolazine ErRanolazine | 24 | $1,802 |
| Prasugrel Hcl | 26 | $1,786 |
| Rosuvastatin Calcium | 136 | $1,561 |
| Metoprolol Succinate | 145 | $1,434 |
| Carvedilol | 139 | $1,056 |
| ClopidogrelClopidogrel Bisulfate | 140 | $990 |
| Metoprolol Tartrate | 140 | $676 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $144 | $249,848181 claims |
| NovartisEntresto | $127 | $125,662100 claims |
| Johnson & JohnsonXarelto | $74 | $28,18023 claims |
| AstraZenecaBrilinta | $224 | $24,71326 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 62 interventional cardiology providers in Nevada.
Other interventional cardiology in Las Vegas
- Cres MirandaLas Vegas$660K
- Adrian Mercado-AlamoLas Vegas$118K
- Nayab ZafarLas Vegas$102K
- William ChuLas Vegas$75K
- Leon VarjabedianLas Vegas$34K
- Moniz DawoodLas Vegas$29K
- Andrew LuxhojLas Vegas$22K
- Mohi AlkadriLas Vegas$20K
- John BedottoLas Vegas$20K
- James LallyLas Vegas$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.